Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
56.07
-1.67 (-2.89%)
Feb 21, 2025, 4:00 PM EST - Market closed
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Rhythm Pharmaceuticals stock have an average target of 66.9, with a low estimate of 52 and a high estimate of 80. The average target predicts an increase of 19.32% from the current stock price of 56.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $64 | Strong Buy | Reiterates | $64 | +14.14% | Feb 19, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $75 | Buy | Reiterates | $75 | +33.76% | Dec 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $69 | Strong Buy | Reiterates | $69 | +23.06% | Dec 23, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $76 | Buy | Initiates | $76 | +35.54% | Dec 20, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $59 → $66 | Strong Buy | Maintains | $59 → $66 | +17.71% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
128.98M
from 77.43M
Increased by 66.58%
Revenue Next Year
186.55M
from 128.98M
Increased by 44.63%
EPS This Year
-4.41
from -3.20
EPS Next Year
-2.63
from -4.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 136.8M | 208.1M | 420.0M | |||
| Avg | 129.0M | 186.6M | 329.9M | |||
| Low | 121.5M | 161.4M | 273.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 76.7% | 61.3% | 125.1% | |||
| Avg | 66.6% | 44.6% | 76.8% | |||
| Low | 56.9% | 25.1% | 46.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.22 | -2.14 | -0.05 | |||
| Avg | -4.41 | -2.63 | -1.05 | |||
| Low | -4.53 | -2.81 | -1.94 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.